INVO

INVO Bioscience earns a Neutral rating with 3/5 conviction, anchored by a composite score near 39. Regulatory is the strongest pillar at roughly 49, supported by a midrange jurisdiction posture and a high enforcement subscore. Market ranks second near 40, although the absence of an available institutional quote limits confirmation from institutional pricing feeds. Fundamentals score approximately 35 as exceptional top-line expansion is offset by weak profitability, limited scale, and constrained cash runway. Editorial contributes the least at 30, reflecting no newsroom or brief activity in CIN newsroom coverage. The resulting profile supports neither a premium stance nor an outright bearish rating.

Revenue increased approximately 481% year over year, earning the maximum revenue-growth subscore, but the quality of that expansion remains poor. Gross margin was only about 9.3%, while operating margin fell below negative 103%, driving the operating-profitability subscore to zero. Net loss approached $7.1 million and EBITDA remained negative by roughly $4.6 million; those figures reinforce the stretched financial condition despite rapid sales growth. A cash-burn ratio near 1.42 and a cash-runway subscore of 15 further constrain the fundamentals pillar. Regulatory evidence is mixed: primary regulatory filings show no recorded events during either the past 90 days or 180 days, no enforcement hits, and no available latest-filing date. That combination supports a strong enforcement component but leaves filing cadence at only 25.

The clearest rerating path runs through the regulatory pillar, already the company’s highest-scoring category. A current primary filing, followed by a more consistent cadence, would strengthen disclosure visibility and could lift the composite without relying on unsupported market pricing or absent editorial momentum. Regulatory progress also carries added importance because weak margins, negative EBITDA, a material net loss, and elevated cash burn leave little capacity for execution slippage. The single most important signal to watch is the appearance of a current primary regulatory filing that establishes a dependable disclosure cadence.